Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.13 is 60% below its 2-year average of 0.33, near the low end of its 2-year range (0.00–0.49).
As of the fiscal period ended Tuesday, March 31, 2026. 62.46% below its 12-month average of 0.35.
Reported quarterly debt to equity ratio; no daily interpolation. Q4 FY2026 (2026-03-31): 0.13.
DEBT TO EQUITY RATIO
0.13
DEBT TO EQUITY RATIO AVG TTM
0.35
DEBT TO EQUITY RATIO AVG 3Y
N/A
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-62.46%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 773 covered companies
CURRENT VS SECTOR MEDIAN
+19.35%
vs the sector median at left
Cellyan Biotechnology Co., Ltd
Market Cap
$1.13M
Debt to Equity Ratio
0.13
TTM Avg
0.35
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.12M
Debt to Equity Ratio
0.05
TTM Avg
0.07
3Y Avg
0.07
5Y Avg
0.07
Market Cap
$1.08M
Debt to Equity Ratio
0.14
TTM Avg
0.76
3Y Avg
0.50
5Y Avg
0.30
Market Cap
$1.01M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$946332.00
Debt to Equity Ratio
0.02
TTM Avg
0.04
3Y Avg
0.04
5Y Avg
1.83
Market Cap
$1.34M
Debt to Equity Ratio
0.01
TTM Avg
0.02
3Y Avg
0.01
5Y Avg
0.01
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cellyan Biotechnology Co., Ltd (HKPD) | $1.13M | 0.13 | 0.35 | N/A | N/A |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.12M | 0.05 | 0.07 | 0.07 | 0.07 |
| IM Cannabis Corp. (IMCC)vs › | $1.17M | N/A | 2.19 | 1.26 | 0.86 |
| Clearmind Medicine Inc. (CMND)vs › | $1.08M | 0.14 | 0.76 | 0.50 | 0.30 |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.01M | 0.00 | 0.00 | 0.00 | 0.00 |
| Sunshine Biopharma, Inc. (SBFM)vs › | $946332.00 | 0.02 | 0.04 | 0.04 | 1.83 |
| Genprex, Inc. (GNPX)vs › | $1.32M | 0.00 | 0.00 | 0.00 | 0.00 |
| NewcelX Ltd. (NCEL)vs › | $1.33M | 0.06 | 0.03 | 0.02 | 0.01 |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.34M | 0.01 | 0.02 | 0.01 | 0.01 |
| GlucoTrack, Inc. (GCTK)vs › | $901902.00 | N/A | 0.01 | 0.08 | 0.06 |
Debt/Equity
0.13
Current Ratio
3.86
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-03-31 | 0.13 |
| 2025-09-30 | 0.44 |
| 2025-03-31 | 0.48 |
| 2024-09-30 | 0.44 |
| 2024-03-31 | 0.49 |
| 2023-09-30 | 0.00 |
